Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

Increase the proportion of people with sickle cell disease on Medicare who received disease-modifying therapies — BDBS‑02 Data

Status: Baseline only

  Baseline only

Most Recent Data:
12.4 percent (2016)

Target:
15.9 percent

Desired Direction:
Increase desired

Baseline:
12.4 percent of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia received disease modifying therapies in accordance with the National Heart, Lung, and Blood Institute (NHLBI)'s guidelines in 2016

Disparities data are only available for some selections.

View CI in the chart by hovering over a data point.

View SE in the chart by hovering over a data point.

Confidence Interval (CI) not available Standard Error (SE) not available Confidence Interval (CI) and Standard Error (SE) are not available